je.st
news
Tag: phase
Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
2015-11-15 01:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Results from C-EDGE CO-STAR Presented at The Liver Meeting Show High Sustained Virologic Response After 12 Weeks of Treatment KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the companys Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting
2015-11-15 01:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
New 8-Bit Digital Phase Shifters From Pasternack Offer 360 Degrees Of Highly Accurate Variable Phase Shift
2015-11-13 08:01:47| rfglobalnet News Articles
Pasternack, a leading provider of RF, microwave and millimeter wave products, introduces a new series of8-bit digital phase shifterswhich are programmable over a full 360°range and can produce a discrete set of phase states of up to 255 total steps with 1.4° increments with a high level of accuracy and minimal phase shift error.
Tags: offer
digital
highly
accurate
Alberta groups call for earlier phase out of coal-fired power
2015-11-10 15:00:00| Climate Ark Climate Change & Global Warming Newsfeed
Calgary Herald: With three weeks to go before the international climate change talks in Paris, a coalition of 44 groups is urging the province to speed up the phase-out of coal-fired electricity in Alberta. The groups, which include professional organizations representing doctors and nurses, are approaching the issue from a public health perspective. "This is really a win-win on multiple fronts," said Dr. Joe Vipond of the Canadian Association of Physicians for the Environment. "When we talk about phasing...
Tags: power
call
groups
earlier
How to Perform a Gloved Phase Transfer Part 2
2015-11-09 21:56:00| Transmission & Distribution World
T&D How: Crew completing all three phases of the gloved wire transfer. Host utility: KCP&L. Sponsored by: Burns & McDonnell read more
Tags: part
transfer
perform
phase
Sites : [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] next »